

30 January 2026

## CARETEQ'S Q2 FY26 ACTIVITIES REPORT AND APPENDIX 4C

### Disciplined operating cash performance – robust runway

CaretEQ Limited (ASX: CTQ) ("CaretEQ" or "the Company"), a clinical healthtech company specialising in innovative medication management and clinical governance solutions, is pleased to provide the following quarterly update and commentary on its Appendix 4C for the quarter ending 31 December 2025.

#### Highlights

- Cash receipts of \$2.1m for the quarter and \$4.02m for H1 FY26.
- Net Operating cash flow \$(0.1m) for Q2 and \$(0.36m) for the half. This includes one off costs associated with the ATO matter of \$0.08m for the quarter and \$0.22m for the half.
- Embedded Health Solutions continues to experience strong growth following on from Q1 with facilities under contract now exceeding 60,000 aged care beds at the end of H2.
- Pricing received from new specialist firm completion of the integration of the 1-System platform for Embedded Health Solutions (EHS) and HMR Referrals with the project commenced this month.
- ATO R&D – We are waiting for the formal objection process to commence with our objections officer recently being appointed.

#### Operational Improvements

The company continues to demonstrate strong operational discipline with underlying operating cash outflow of \$(0.02m) for the quarter. The company did incur one off costs of \$0.08m associated with the ATO matter that is currently going through an objection process that impacted the overall operating cash flow of the group .

#### Embedded Health Solutions (EHS) and HMR Referrals

EHS delivered another quarter of growth, with facilities under contract now 667, and in excess of 60,000 aged-care beds, an increase of ~9% for the quarter. The sales pipeline of new facilities remains encouraging, with a number of opportunities deep into the process and support continued growth over the coming quarters.

The delivery of the 1-System platform has recommenced this month with a specialist firm engaged to complete the project with completion expected to be completed by year end.

## ATO position update

The Company advised last quarter that through its legal advisers it had lodged a formal objection to the previously disclosed ATO issued amended assessments on 29 May 2025 following its review of Careteq's R&D Tax Incentive claims for FY21–FY23.

Objections Officer appointed recently and the process remains ongoing. We will continue to engage constructively with the ATO, supported by our legal advisers MinterEllison.

The Board will keep shareholders and the market informed as appropriate.

## Financial overview

The Company is encouraged with the first half performance and remains committed to continue its pursuit of achieving a sustainable positive cash flow and profitability, supported by its disciplined financial management.

In accordance with ASX Listing Rule 4.7C.3, payments to related parties and their associates totalling \$57k outlined in Item 6 of the Company's Appendix 4C relate to director fees, salaries, and superannuation.

**This ASX announcement has been authorised by the Board of Careteq Limited (ASX: CTQ)**

**For further information, please contact:**

**Careteq Limited (ASX: CTQ)**

Mark Simari  
Executive Chairman  
P: +61 3 8866 5594  
E: info@careteq.com.au

## About Careteq Limited (ASX: CTQ)

Careteq Limited (ASX: CTQ) is an Australian healthtech company focused on innovative medication management solutions. The Company is dedicated to improving healthcare outcomes through its fully owned Embedded Health Solutions (EHS) and HMR Referrals platforms. EHS provides comprehensive aged care medication management solutions through Residential Medication Management Reviews (RMMRs), while HMR Referrals streamlines Home Medicines Reviews (HMRs).

To learn more, please visit: [www.careteq.com.au/](http://www.careteq.com.au/)

## Forward-looking statements

This announcement contains or may contain forward-looking statements that are based on Careteq's beliefs, assumptions, and expectations and on information currently available to Careteq. All statements that address operating performance, events or developments that Careteq or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of Careteq or the market it operates in.

Careteq believes that these forward-looking statements are reasonable as and when made. You should not place

undue reliance on forward-looking statements because they speak only as of the date when made. Careteq does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

No assurance or guarantee is, or should be taken to be, given in relation to, and no reliance should be placed on, the future business performance or results of Careteq or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

**For more information**



Follow us on [LinkedIn](#)

To learn more about Careteq please click here: <https://www.careteq.com.au/investors-centre/>

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity			
Careteq Limited			
ABN		Quarter ended (“current quarter”)	
83 612 267 857		31 December 2025	
<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>			
1.1 Receipts from customers		2,098	4,022
1.2 Payments for			
(a) research and development		-	-
(b) product manufacturing and operating costs		(27)	(53)
(c) advertising and marketing		(10)	(30)
(d) leased assets		-	-
(e) staff costs		(1,626)	(3,266)
(f) administration and corporate costs		(494)	(1,003)
1.3 Dividends received		-	-
1.4 Interest received		4	4
1.5 Interest and other costs of finance paid		(6)	(17)
1.6 Income taxes paid		(24)	(24)
1.7 Government grants and tax incentives		(10)	6
1.8 Other (provide details if material)		-	-
<b>1.9 Net cash from / (used in) operating activities</b>		<b>(95)</b>	<b>(361)</b>
<b>2. Cash flows from investing activities</b>			
2.1 Payments to acquire or for:			
(a) entities		-	-
(b) businesses		-	-
(c) property, plant and equipment		(22)	(41)
(d) investments		-	-
(e) intellectual property		-	-
(f) other non-current assets		-	-

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
2.2 Proceeds from disposal of:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
<b>2.6 Net cash from / (used in) investing activities</b>	<b>(22)</b>	<b>(41)</b>
<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2 Proceeds from issue of convertible debt securities	-	-
3.3 Proceeds from exercise of options	-	-
3.4 Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5 Proceeds from borrowings	-	47
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid (Note 3)	-	-
3.9 Other (provide details if material)	-	-
<b>3.10 Net cash from / (used in) financing activities</b>	<b>-</b>	<b>47</b>
<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of period	788	1,027
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(95)	(361)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(22)	(41)

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
4.4	Net cash from / (used in) financing activities (item 3.10 above)	–	47
4.5	Effect of movement in exchange rates on cash held	(2)	(3)
4.6	<b>Cash and cash equivalents at end of period</b>	<b>669</b>	<b>669</b>

<b>5. Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts		<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	669	669
5.2	Call deposits	–	–
5.3	Bank overdrafts	–	–
5.4	Other (provide details)	–	–
5.5	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>669</b>	<b>669</b>

<b>6. Payments to related parties of the entity and their associates</b>		<b>Current quarter \$A'000</b>
6.1	Aggregate amount of payments to related parties and their associates included in item 1	57
6.2	Aggregate amount of payments to related parties and their associates included in item 2	

*Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.*

<b>7. Financing facilities</b>		<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
<i>Note: the term 'facility' includes all forms of financing arrangements available to the entity.</i>			
<i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>			
7.1	Loan facilities	125	125
7.2	Credit standby arrangements	—	—
7.3	Other (Convertible Note)	500	500
7.4	<b>Total financing facilities</b>	625	625
7.5	<b>Unused financing facilities available at quarter end</b>		0
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	<p>As announced to the market on 10 and 13 June 2025, the Company entered in a binding convertible note agreement with Mr Antanas Guoga (Tony G) for \$500,000. The note carries a coupon rate of 12% per annum, which is included in the face value and is payable through the issue of fully paid ordinary shares in Careteq Ltd at a conversion price of \$0.01 per share. The notes will mature on 4 June 2026.</p> <p>Further, as announced on 10 June 2025, all members of the Board including its Company Secretary entered into a binding loan agreement to raise \$125,000. The interest rate on each loan is 12% per annum and mature on 4 June 2026. The breakdown is as follows:</p> <ul style="list-style-type: none"> <li>• Mr Mark Simari (Executive Chair) – loan amount of \$26,500</li> <li>• Mr Brett Cheong (Non-Executive Director) – loan amount of \$26,500</li> <li>• Mr Stephen Munday (Non-Executive Director) – loan amount of \$47,000</li> <li>• Mr David Lilja (Company Secretary) – loan amount of \$26,500</li> </ul>		

<b>8. Estimated cash available for future operating activities</b>		<b>\$A'000</b>
8.1	Net cash from / (used in) operating activities (item 1.9)	(95)
8.2	Cash and cash equivalents at quarter end (item 4.6)	669
8.3	Unused finance facilities available at quarter end (item 7.5)	—
8.4	Total available funding (item 8.2 + item 8.3)	669
8.5	<b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	7.0

*Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.*

- 8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:
- 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

- 8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

- 8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

*Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.*

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: .....30<sup>th</sup> January 2026.....

Authorised by: .....By the Board of Directors of Careteq Limited.....  
(Name of body or officer authorising release – see note 4)

### Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends paid may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. *Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.